Currently, the most established strategy for targeting the mTOR pathway involve directly inhibiting the tumor's mTOR pathway to reduce its metabolic rate, thereby alleviating the burden on NK cells for substance and energy uptake in the TME. This evidence concerns the gene MTOR and neoplasm.